Patients with an advanced form of lung cancer lived 56 percent longer without their disease progressing when radiotherapy was added to the standard of care whole-body therapy, including chemotherapy and/or immunotherapy, according to initial results from a clinical trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.
